High density lipoprotein subpopulations from galactosamine-treated rats and their transformation by lecithin:cholesterol acyltransferase.
It is known that an acute hepatotoxicity is produced in rats by intraperitoneal administration of galactosamine; a consequence of this treatment is a marked deficiency of lecithin:cholesterol acyltransferase (LCAT) activity in the plasma compartment. In this study high density lipoprotein (HDL) from galactosamine-treated rats was isolated, resolved into subpopulations, and characterized. In contrast to HDL from control rats, which elutes from gel filtration columns as a single peak and has a diameter of 13.1 nm, HDL from the galactosamine-treated animals was found to elute in five major zones with diameters of 7.8-35 nm. Characterization of these subpopulations has revealed that the larger fractions are enriched in apolipoprotein E, phospholipid, and cholesterol, but contain little cholesteryl ester, while the smallest two fractions contain mainly apolipoprotein A-I, are enriched in phospholipid, and have 50-60% of their cholesterol in the ester form. Incubation of HDL from treated rats with a source of LCAT activity plus low and very low density lipoproteins caused transformation of these subpopulations into a species which, by size and composition, was essentially identical to control rat HDL. In addition, when the subpopulations were individually incubated with purified human lecithin:cholesterol acyltransferase and bovine serum albumin, there was a similar convergence toward a moderate particle size approximating control rat HDL. Cross-linking studies showed that incubation with LCAT activity reduced the heterogeneity of the treated rat HDL. We conclude that the galactosamine treatment induces a complex mixture of HDL that bears strong similarities to the small, apoA-I rich and large, apoE-rich particles seen in LCAT deficiency or secreted by hepatic cells in culture. Furthermore, these species appear to coalesce in the presence of the d greater than 1.21 g/ml fraction of control serum to yield a fairly homogeneous population that resembles control rat HDL in size, composition, and apoprotein content.
Matsuura
J E
JE
Department of Biological Chemistry, Hahnemann University, Philadelphia, PA 19102.
Swaney
J B
JB
D000818:Animals; D016632:Apolipoprotein A-I; D001054:Apolipoproteins A / Q000378:metabolism; D001057:Apolipoproteins E / Q000097:blood; D005591:Chemical Fractionation; D002788:Cholesterol Esters / Q000378:metabolism; D003432:Cross-Linking Reagents; D003720:Densitometry; D005688:Galactosamine / Q000494:pharmacology*; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood* / Q000145:classification / Q000302:isolation & purification; D008297:Male; D008970:Molecular Weight; D010316:Particle Size; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood / Q000502:physiology*; D010743:Phospholipids / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains
D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D001057:Apolipoproteins E; D002788:Cholesterol Esters; D003432:Cross-Linking Reagents; D008075:Lipoproteins, HDL; D010743:Phospholipids; D005688:Galactosamine; D007862:Phosphatidylcholine-Sterol O-Acyltransferase